Skip to main content
NCBI home page
Annals of the Rheumatic Diseases logoLink to Annals of the Rheumatic Diseases
. 1984 Aug;43(4):586–589. doi: 10.1136/ard.43.4.586

Serum amyloid A protein concentration in progressive systemic sclerosis (scleroderma).

S R Brandwein, T A Medsger Jr, M Skinner, J D Sipe, G P Rodnan, A S Cohen
PMCID: PMC1001414  PMID: 6476917

Abstract

Serum amyloid A protein (SAA) concentrations were determined in 62 patients with progressive systemic sclerosis (PSS). Forty-seven patients had normal or slightly elevated SAA levels (less than 1000 ng/ml = micrograms/l), while 15 patients had moderately to markedly elevated SAA levels, similar to those observed in active rheumatoid arthritis (RA) (greater than or equal to 1000 ng/ml = micrograms/l). Five patients with PSS had SAA levels corresponding to those observed in amyloidosis secondary to RA. High SAA was associated with more severe skin thickening and diminished cumulative survival at five years. The rarity of amyloidosis secondary to PSS is unlikely to be related to an intrinsic defect in SAA production.

Full text

PDF
586

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Holzmann H., Korting G. W. Perikollagene Amyloidablagerungen in Haut und inneren Organen bei Sklerodermie. Klin Wochenschr. 1969 Apr 1;47(7):390–391. doi: 10.1007/BF01734768. [DOI] [PubMed] [Google Scholar]
  2. Horwitz H. M., DiBeneditto J. D., Jr, Allegra S. R., Baumann H. M. Scleroderma, amyloidosis, and extensor tendon rupture. Arthritis Rheum. 1982 Sep;25(9):1141–1143. doi: 10.1002/art.1780250919. [DOI] [PubMed] [Google Scholar]
  3. Levin M., Pras M., Franklin E. C. Immunologic studies of the major nonimmunoglobulin protein of amyloid. I. Identification and partial characterization of a related serum component. J Exp Med. 1973 Aug 1;138(2):373–380. doi: 10.1084/jem.138.2.373. [DOI] [PMC free article] [PubMed] [Google Scholar]
  4. Lowe W. C. Scleroderma and amyloidosis. Mil Med. 1969 Nov;134(12):1430–1433. [PubMed] [Google Scholar]
  5. ROPES M. W., BENNETT G. A., COBB S., JACOX R., JESSAR R. A. 1958 Revision of diagnostic criteria for rheumatoid arthritis. Bull Rheum Dis. 1958 Dec;9(4):175–176. [PubMed] [Google Scholar]
  6. Seibold J. R., Iammarino R. M., Rodnan G. P. Alpha-1-antitrypsin in progressive systemic sclerosis. Arthritis Rheum. 1980 Mar;23(3):367–370. doi: 10.1002/art.1780230319. [DOI] [PubMed] [Google Scholar]
  7. Sipe J. D., Ignaczak T. F., Pollock P. S., Glenner G. G. Amyloid fibril protein AA: purification and properties of the antigenically related serum component as determined by solid phase radioimmunoassay. J Immunol. 1976 Apr;116(4):1151–1156. [PubMed] [Google Scholar]
  8. Sipe J. D., Vogel S. N., Ryan J. L., McAdam K. P., Rosenstreich D. L. Detection of a mediator derived from endotoxin-stimulated macrohpages that induces the acute phase serum amyloid A response in mice. J Exp Med. 1979 Sep 19;150(3):597–606. doi: 10.1084/jem.150.3.597. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Steen V. D., Medsger T. A., Jr, Rodnan G. P. D-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982 Nov;97(5):652–659. doi: 10.7326/0003-4819-97-5-652. [DOI] [PubMed] [Google Scholar]
  10. Sztein M. B., Vogel S. N., Sipe J. D., Murphy P. A., Mizel S. B., Oppenheim J. J., Rosenstreich D. L. The role of macrophages in the acute-phase response: SAA inducer is closely related to lymphocyte activating factor and endogenous pyrogen. Cell Immunol. 1981 Sep 1;63(1):164–176. doi: 10.1016/0008-8749(81)90037-x. [DOI] [PubMed] [Google Scholar]

Articles from Annals of the Rheumatic Diseases are provided here courtesy of BMJ Publishing Group

RESOURCES